Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Finished Goods: 2023-2025

Historic Finished Goods for Tonix Pharmaceuticals Holding (TNXP) over the last 1 years, with Sep 2025 value amounting to $1.8 million.

  • Tonix Pharmaceuticals Holding's Finished Goods fell 33.09% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 33.09%. This contributed to the annual value of $5.1 million for FY2024, which is 31.58% down from last year.
  • Latest data reveals that Tonix Pharmaceuticals Holding reported Finished Goods of $1.8 million as of Q3 2025, which was down 25.73% from $2.4 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's Finished Goods' 5-year high stood at $7.5 million during Q4 2023, with a 5-year trough of $1.8 million in Q3 2025.
  • Moreover, its 3-year median value for Finished Goods was $3.7 million (2024), whereas its average is $4.0 million.
  • Data for Tonix Pharmaceuticals Holding's Finished Goods shows a maximum YoY crashed of 33.09% (in 2025) over the last 5 years.
  • Tonix Pharmaceuticals Holding's Finished Goods (Quarterly) stood at $7.5 million in 2023, then slumped by 31.58% to $5.1 million in 2024, then slumped by 33.09% to $1.8 million in 2025.
  • Its Finished Goods stands at $1.8 million for Q3 2025, versus $2.4 million for Q2 2025 and $4.8 million for Q1 2025.